Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Nektar Therapeutics

Symantec Corp

Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.

3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics

AbbVie

Bristol-Myers

Celgene

Novartis

New blockbusters could be on the way for five drugmakers.

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

CRISPR Therapeutics

Sangamo Therapeutics

Due to its stellar CRISPR/Cas9 platform, CRISPR Therapeutics is able to expand its collaborative relationship with the pharmaceutical elite, Vertex.

Crispr: Vertex Doubled Down On The Reigning Champion CRISPR/Cas9

CELG vs. VRTX: Which Stock Is the Better Value Option?

CELG or VRTX: Which Is the Better Value Stock Right Now?

Sarepta Therapeutics

Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.

Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

Vertex Pharmaceuticals is betting on gene-editing treatments with the acquisition of private biotech company Exonics Therapeutics and a deeper collaboration with Crispr Therapeutics.
The post Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing appeared first on Investor's Business Daily.

Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing

Gene editing is an emerging field, and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)  is plunging headlong into it with two deals announced Thursday after the market close.

Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion

Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.

Vertex Expands Collaboration With CRISPR, Acquires Exonics

Vertex picks VX-445 as triplet therapy to move on with for regulatory approval in the U.S. and European Union to treat patients with cystic fibrosis.

Vertex's Latest Data May Lead To Expanded Cystic Fibrosis Market

Gilead Sciences

Illumina

Repligen

Bio-Techne

here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.

5 Biotech Stocks to Buy Right Now

Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

Vertex Selects Triple Combo Regimen for Regulatory Submission

Vertex Pharmaceuticals said Thursday it selected the three-drug cystic fibrosis treatment it plans to submit to regulators in the U.S. and Europe.

This Biotech Just Inched Closer To Treating 90% Of Cystic Fibrosis Patients

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?

Why Is Vertex (VRTX) Down 3.5% Since Last Earnings Report?

Align Technology

Waste Connections

Several large-cap stocks have had positive performances over the past month, year to date, the last 12 months and past three years.

3 Large-Cap Stocks With Superior Performances

CEO & President of Vertex Pharmaceuticals Inc. Jeffrey M Leiden sold 113,432 shares of VRTX on 05/24/2019 at an average price of $175.1 a share.

Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $19.9 million of Shares

Alexion Pharma

BioMarin Pharmaceutical

There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.

3 Big Biotech Stocks That Warren Buffett Might Like

Allergan

Regeneron Pharmaceuticals

XBiotech

Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?

5 Growthy Biotech Stocks to Buy Despite the Scrutiny

This biotech checks off the two most important criteria that the greatest stocks have.

My Top Stock to Buy in May

CELG vs. VRTX: Which Stock Should Value Investors Buy Now?

The biotech's cystic fibrosis treatment potential is far from over.

Vertex Pharmaceuticals Looks to Jump From 18,000 Patients to 68,000

Vertex started off 2019 on a positive note. But even better days are almost certainly on the way.

5 Things You Need to Know From Vertex Pharmaceuticals' Q1 Earnings Update

Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.

Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates

Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q1 2019 Results - Earnings Call Transcript

Vertex earnings of $1.14 a share on $857 million in sales beat the forecasts of Wall Street analysts when it reported late Tuesday. But Vertex stock remained flat in after-hours action.

Cystic Fibrosis-Focused Biotech Easily Tops First-Quarter Estimates

GW Pharmaceuticals

The future looks incredibly bright for these three businesses.

News for Vertex Pharmaceuticals Stock (VRTX)